Stage 4 Cancer Patient Shows No Disease After Experimental Transplant

In May 2024, Amy Piccioli walked into a Los Angeles emergency room complaining of dehydration. She walked out with a Stage 4 colorectal cancer diagnosis. At 39, with no family history of the disease and no prior symptoms, imaging revealed a mass in her colon that had already metastasized, seeding lesions throughout her liver [1].

The prognosis was stark. For patients with unresectable colorectal liver metastases — tumors that have spread to the liver and cannot be surgically removed — five-year survival rates with chemotherapy alone hover around 10% [3]. But Piccioli's story did not end with that statistic. Three months after undergoing a living donor liver transplant at Northwestern Medicine in Chicago in December 2025, her doctors delivered news that would have been nearly unthinkable a decade ago: she currently has "no evidence of disease" [1].

Her case sits at the intersection of a devastating public health trend and a quietly revolutionary medical advance — one that is forcing the oncology and transplant communities to rethink who deserves a scarce organ and what "terminal" really means.

A Cancer Crisis Among the Young

Piccioli's diagnosis at 39 places her squarely within a demographic that has alarmed cancer researchers for the past decade. Colorectal cancer is now the leading cause of cancer-related death among men and women under age 50 in the United States, a grim milestone reached in 2023 — seven years sooner than epidemiologists had projected [7][8].

The numbers are staggering. In 2026, an estimated 158,850 new cases of colorectal cancer will be diagnosed in the U.S., and 55,230 people will die from the disease [4]. Among Americans ages 20 to 49, incidence is climbing at roughly 3% per year, and the disease is projected to increase by 90% in that age group by 2030 [7]. Today, nearly one in five colorectal cancer diagnoses occurs in someone under 55, up from approximately one in ten two decades ago [4].

Perhaps most troubling is that younger patients are disproportionately diagnosed at advanced stages. Three in four colorectal cancers in adults younger than 50 are diagnosed at a regional or distant stage, in part because screening prevalence among 45- to 49-year-olds stands at just 37% [4]. By the time many young patients learn they have the disease, it has already spread — most commonly to the liver.

Up to 60% of colorectal cancer patients will eventually develop liver metastases, and for those whose tumors are deemed unresectable, treatment options have historically been limited to systemic chemotherapy with palliative intent [3].

Source: GDELT Project

Data as of Mar 12, 2026CSV

The Transplant Breakthrough

The idea of using liver transplants to treat colorectal metastases is not entirely new. Norwegian researchers at Oslo University Hospital pioneered the approach with the SECA-I trial, first reported in 2013, which demonstrated a five-year overall survival rate of 60% — a remarkable improvement over the 10% benchmark with chemotherapy alone [6]. A subsequent SECA-II trial, applying more stringent patient selection criteria, pushed that figure to 83% [6].

But the definitive proof came from TRANSMET, a multicenter European randomized controlled trial — the first of its kind — comparing liver transplantation plus chemotherapy against chemotherapy alone. The results, presented at the American Society of Clinical Oncology (ASCO) annual meeting, were striking [6]:

• Five-year overall survival (per-protocol): 73% with transplant vs. 9% with chemotherapy alone
• Hazard ratio: 0.16 (P < .0001)
• Five-year progression-free survival: 20% with transplant vs. 0% with chemotherapy
• No evidence of disease: 42% of transplant recipients at long-term follow-up (median 50 months)

The data carried an important caveat: 72% of transplant recipients experienced disease recurrence, primarily in the lungs and lymph nodes. But unlike recurrence in a transplanted liver, these metastases were often amenable to rescue surgery or ablation. Nearly half of patients who recurred underwent successful salvage procedures [6].

"Liver transplant for patients with unresectable colorectal cancer can be a lifesaving and potentially curative treatment for patients who are otherwise facing very dismal prognosis," said Dr. Zachary Dietch, an assistant professor of surgery and abdominal organ transplant surgeon at Northwestern Medicine, who was involved in Piccioli's care [1].

Source: ASCO Post / SECA Trials / TRANSMET Trial

Data as of Mar 12, 2026CSV

A Friend's Gift

For Piccioli, the path to transplant required navigating a system that was not designed for patients like her. After multiple rounds of chemotherapy and immunotherapy, she and her medical team explored transplant as an option. She was referred to Northwestern Medicine, which operates one of the few liver transplant programs in the United States specifically designed for colorectal cancer patients with hepatic metastases [1][2].

The critical challenge was finding a donor. The U.S. organ transplant system does not prioritize cancer patients for deceased donor livers in the same way it does patients with liver failure from other causes. As Dr. Satish Nadig, director of the Northwestern Medicine Comprehensive Transplant Center, has noted: "Because liver transplantation for colorectal cancer is not done at many centers around the country, the current organ allocation system does not prioritize these patients" [3].

Enter Lauren Prior. A 37-year-old mother of three from Glenview, Illinois, Prior was a close family friend of Piccioli's. When she learned about the need for a living donor, she got tested — and turned out to be a match [1].

"It's such a small sacrifice to make that could potentially save someone's life, or at least improve their quality of life," Prior told ABC News [1].

The surgery took place in December 2025. Surgeons removed Piccioli's diseased liver and replaced it with a portion of Prior's healthy one. The living liver has a remarkable capacity to regenerate; within weeks, both the donor's remaining liver and the transplanted portion grow back to near-normal size.

Three months later, scans showed no detectable cancer. Piccioli continues to take anti-rejection medication and requires ongoing monitoring, but the immediate results represent what her care team described as a best-case outcome [1].

The CLEAR Program and the RAPID Procedure

Piccioli's case is one piece of a broader institutional effort at Northwestern Medicine to expand access to transplant for cancer patients. In March 2025, the hospital launched the CLEAR program — Colorectal Metastasis to Liver Extraction with Auxiliary Transplant and Delayed Resection — a dedicated clinical initiative designed to systematically offer transplant as a treatment pathway [3].

Central to CLEAR is the RAPID procedure (Resection and Partial Liver Transplantation with Delayed Total Hepatectomy), a two-stage surgical technique that addresses one of the field's most persistent problems: the shortage of donor organs [3].

In a RAPID procedure, surgeons take a deceased donor liver — already allocated to a higher-priority patient on the transplant waitlist — and split it. The larger portion goes to the originally designated recipient. The smaller graft is transplanted into the cancer patient, who simultaneously has half of their diseased liver removed. Within approximately two weeks, the small graft regenerates to functional size, at which point surgeons return to remove the remaining cancerous liver tissue [3].

The approach is elegant in its efficiency: one donor organ serves two patients, and the cancer patient receives a transplant without diverting a whole organ from the existing allocation queue.

Barclay Missen, a 53-year-old Chicago resident, became the first RAPID recipient at Northwestern in October 2024. Four months after the procedure, he showed no evidence of cancer and required no additional cancer therapy [3].

Northwestern Medicine has performed more than 2,700 liver transplants in its history, including 138 in 2024 — 17 of which involved living donors [3]. The CLEAR program's research registry aims to track outcomes for the first 80 patients, building the evidence base that could eventually reshape national transplant policy.

The Ethical Tightrope

The clinical promise of transplant oncology comes freighted with difficult ethical questions. The United States faces a chronic organ shortage: as of September 2024, more than 9,400 patients were on the liver transplant waiting list [9]. Every eight minutes, another person is added to the national organ transplant queue [9]. Only about 3 in every 1,000 deaths occur in a way that allows for organ donation [9].

Expanding transplant eligibility to include cancer patients — particularly those with metastatic disease, who were long considered categorically ineligible — raises fundamental questions about allocation. Should a patient with colorectal liver metastases, who has a 73% chance of five-year survival with a transplant, receive an organ over a patient with acute liver failure? What about over a patient with alcoholic cirrhosis? The answers depend heavily on which ethical framework one applies: maximizing total life-years saved, prioritizing the sickest patients, or rewarding time spent waiting [10].

The living donor model and the RAPID split-liver technique partially sidestep these dilemmas by expanding the effective organ supply rather than reallocating from existing pools. But as the field grows and more cancer types are evaluated for transplant eligibility — hepatocellular carcinoma criteria have already been progressively expanded — pressure on the donor organ supply will intensify [10].

"There is no widely accepted single ethical principle for the fair allocation of scarce donor organs," acknowledged a review in the Journal of Ethics published by the American Medical Association. Most systems rely on "combinations of allocation principles with particular tension between 'prioritizing the worst-off' and 'maximizing total benefits'" [10].

What Comes Next

The emergence of transplant oncology as a viable discipline represents a paradigm shift in how the medical community thinks about Stage 4 cancer. For decades, metastatic colorectal cancer to the liver was treated as a death sentence — managed, not cured. The TRANSMET trial and cases like Piccioli's and Missen's are challenging that assumption with data.

Several factors will determine how quickly this approach scales. Insurance coverage and cost remain significant barriers; liver transplants can cost upwards of $800,000, and payer policies for oncologic indications are still evolving. The number of transplant centers with the specialized expertise to evaluate and operate on cancer patients remains small. And the fundamental constraint of organ availability, while partially addressed by living donation and split-liver techniques, will not disappear.

But for the growing number of young Americans being diagnosed with advanced colorectal cancer — a population that is expanding at an alarming rate and is increasingly the face of this disease — the existence of a treatment option that offers a 73% chance of being alive in five years, rather than 9%, is not an incremental improvement. It is a transformation.

Amy Piccioli, now cancer-free and recovering in Los Angeles, put it more simply. Her story, and the friend who made it possible, represent what transplant oncology aspires to deliver: not just more time, but the possibility of a cure where none existed before [1].